General Motors
BP
Ford Motor Company
AstraZeneca
DaimlerChrysler
CNN
General Electric
US Senate
Credit Suisse First Boston
Volkswagen
Siemens
Philip Morris
Bloomberg
Verizon
AT&T
FIAT
Nestle
AT&T
General Dynamics
Lloyds
General Electric
General Motors
Hewlett Packard
ABN Amro
Swiss Army
UBS Warburg
Merrill Lynch
New York Stock Exchange
General Motors
The Economist
France Telecom
Boeing
Lafarge
Safeway
People's Republic of China's
Ministry of Agriculture
Siemens
Nordea
Tesco
Britvic Softdrinks
Pfizer
Philips
UK Department of Trade & Industry
US Department of Defense
Lloyds
Sybase
Sprint
New York Life Insurance
BBC
3
Canon USA
Novell
Ericsson
AstraZeneca
EDS
Philip Morris International
Royal & SunAlliance
Novartis
Credit Lyonnais
Sun Microsystems
British American Tobacco
Philips
Norsk Hydro
Sun Microsystems
AstraZeneca
Sun Microsystems
Skanska
BAE Systems
Kodak
The Royal Mail Group
Henkel
US State Department
Bank of Montreal
Danske Bank
BMW
Kronos Corporation
Fujitsu Technology Services
Zurich Financial Services
Halliburton
Hewlett Packard
BBC
Blue Cross/Blue Shield of Massachusetts
3
T-Mobile
Channel 4 Corporation
VHA
BP
Burges Salmon
Motorola
British Telecom
Credit Lyonnais
General Motors
Ferrari
Deloitte & Touche
PA Consulting
US Army
UK Department of Trade & Industry
EMC Corporation
US Department of Commerce
3
Encana Corporation
IEEE
Hewitt Associates LLC
HEALTHvision
Nestle
Paramount
Lexmark
MOL
US Department of Defense
JD Edwards
Ingersoll-Rand
PricewaterhouseCoopers
AstraZeneca
Vodafone Omnitel
Nomura
Lloyds
Nestle
US State Department
Macmillan Publishing
Reed Elsevier
Dow Chemical Company
Siemens Power Generation
US State Department
Nestle
Texas Instruments
Forrester Research
McData
Wall Street Journal
Lloyds
NASA
SCA
Reuters
ITN
IBM NICA
The McGraw-Hill Companies
3
Ingersoll-Rand
Royal & SunAlliance
Forbes.com
T-Mobile
Nissan North America, Inc.
Toyota Motor
The McGraw-Hill Companies
Ericsson
Fox Sports
US State Department
3
Society of Petroleum Engineers
US Department of Energy
UK Department of Trade & Industry
Henkel
Vodafone Omnitel
European Commission
ABN Amro
Telecom Italia
Harrah's
AXA
Sybase
BP
Napster
Siemens
Oracle
Philips
Compuware
Olympus
AstraZeneca
ARM
New York Life Insurance
Taylor & Francis
AstraZeneca
Federal Express
Nissan Motor
Danske Bank
Pfizer
US Department of Defense
Milward Brown Precis
Federal Government of Canada
AstraZeneca
Nestle
UK Home Office
HM Revenue & Customs
3
Hewlett Packard
Harvard Business School
BBC
Britvic Softdrinks
MOL
Macmillan Publishing
General Motors
Allianz Life Insurance Co
Swiss Army
Parliament of Singapore
VMS
Singapore Police Force
Sony Music
GSA Advantage!
Kaiser Permanente
Stanford Business School
HM Revenue & Customs
Johns Hopkins
Wachovia
Standard Life Insurance
Raytheon
Philips
Commerzbank
Allstate Insurance
3
State of Washington
Napa Valley County
Texas Department of Transportation
American HomePatient
AstraZeneca
TIBCO
Sharper Image
Xerox
America Online
AT&T
Ericsson
Lockheed Northrop Grumman
Dow Chemical Company
Draeger Medical
US Department of Commerce
Sutter Health
Philips
Kenyan AIDS Clinic
BP
University of Washington
Sun Microsystems
State of Minnesota
World Wildlife Fund
Autonomy Group Customers
 
News
Events
RSS Feeds
Press Release Archives
For Financial News, please see the Investors section of the website.

News VIRAGE ANNOUNCES LIV... | AUTONOMY WINS REPEAT... | CONNECTIONS 2002 UNI...
Press Release
Related Events
Related Case Studies
Related Resources

Autonomy Wins Repeat Business In Pharmaceutical Sector

Leading Pharmaceutical & Medical Companies Purchase Autonomy to Extend Existing Autonomy Enterprise Deployments and to Launch New Autonomy-Powered Web service.

CAMBRIDGE, England, 27 December 2001 - Autonomy Corporation plc (Nasdaq: AUTN; LSE: AU., Nasdaq Europe: AUTN), a global leader in infrastructure software for the enterprise, today announced a series of repeat customer wins in the pharmaceutical and medical sectors, including: Astra Zeneca with three further Autonomy deployments in Europe and North America, extensions to a European implementation earlier this year; Pfizer with a new deployment of Autonomy in Europe, an addition to a previous North American purchase; and Onmedica a new Web-based Autonomy- powered service for doctors and health service suppliers in the UK.

Last year, Astra Zeneca selected Autonomy Server™ for its Product Knowledge Transfer, a major knowledge management project. Autonomy's infrastructure software was integrated into an information portal to automatically aggregate, index and provide access to a wide range of content from legacy systems, publications databases, competitor databases, clinical trials databases and information from the Web. Confirming the subsequent success of their initial deployment, Astra Zeneca has now purchased three additional extensions to their existing deployment in order to support up to 9000 users and meet growing information processing requirements, bringing the total number of Autonomy purchases to four.

Pfizer Sweden recently purchased Autonomy's Portal-in-a-Box™, Autonomy ActiveKnowledge™ and Autonomy Categorizer™ for a business intelligence portal and will conduct a joint implementation of Autonomy's software within Sweden and the UK. Autonomy's infrastructure technology was selected to provide access to the organization's collective resources and enhance Pfizer's world-class information analysis, information exploitation and business intelligence process. With Autonomy, Pfizer Sweden and UK employees will be able to set up personalized agents to track the information that is most relevant to their jobs as well as identify fellow employee's expertise for collaboration. This deployment is additional to a previous deployment of Autonomy in Pfizer in North America.

According to Lynch the pharmaceutical and medical industries are knowledge-rich environments with rapidly changing information that is vital to research, treatment and practises. "Four out of the five leading pharmaceutical companies use Autonomy's technology to power information systems that provide their employees with better access to critical information," said Lynch. "Our increased penetration into this market is a continuing validation of both our technology and our business model."

Finally, Onmedica, a Web-based service for doctors and health service suppliers in the UK, selected Autonomy's technology to automate the delivery of information. Using Autonomy, Onmedica will enable the health service to lower costs and enhance clinicians' ongoing education, by taking clinical, pharmaceutical and product information from multiple sources and automatically performing critical processes on it - such as categorisation, hypertext linking to related information, personalisation to each user's individual needs and identification of other users with similar interests and expertise.

The high degree of automation means that no manual labour is needed to organise the information; the fact that doctors with similar interests and expertise can be automatically put in touch with each other eliminates duplication of research effort; the automatic linking of medical information with details of appropriate products (drugs, prosthetics, dressings) shortens procurement cycles.

Dr. Mike Lynch, founder and group CEO of Autonomy, commented: "Under-funding has dealt a huge blow to clinical education and procurement in this country and Autonomy enables Onmedica to redress that imbalance. Subscription to the Onmedica service will, we believe, quickly pay for itself in terms of the time, knowledge and economies gained. The service is also a valuable marketing channel for pharmaceutical companies. We are pleased to welcome Onmedica to a global clinical and pharmaceutical clientele list that already includes names like Akzo Nobel, Astra Zeneca and Novartis."

At the heart of Autonomy's software is its ability to analyse text and voice and identify and rank the main concepts within it. It can then automatically categorise, link, personalise and deliver that information. Using Autonomy, the information that applications need becomes independent from the data source. This ability to universally interrelate disparate applications, without the need for middleware or XML, is known as Integration Through Understanding; the technology behind it is Autonomy's Interactive Data Operating Layer (IDOL). The technology is used to automate operations within enterprise information portals, customer relationship management, knowledge management and e-business applications, among others.

About Autonomy

Autonomy Corporation plc (Nasdaq: AUTN; Nasdaq Europe: AUTN; LSE: AU.) is a global leader in infrastructure software for the enterprise. Autonomy's technology powers applications dependent upon unstructured information including: e-commerce, customer relationship management, knowledge management, enterprise information portals, enterprise resource planning and online publishing. Autonomy's customer base includes more than 475 global companies, including Astra Zeneca, British Aerospace, Clorox, Deutsche Bank, Ericsson, General Motors, Lucent, Royal SunAlliance, Sun Microsystems and public sector agencies including the United States Department of Defense, NASA and the United States Department of Energy. Strategic reseller and OEM partners include leading companies such as BEA, Business Objects, Hewlett Packard, IBM Global Services, Oracle, Vignette and Sybase. The company has offices in North America, Europe, Asia and Australia and is on the Web at www.autonomy.com.

Caution Concerning Forward-Looking Statements

With the exception of historical information, the matters set forth in this news release are forward-looking statements that involve risks and uncertainties. A number of important factors could cause actual results to differ materially from those in the forward-looking statements. These factors include, among others, technology risks, including dependence on core technology; fluctuations in quarterly results; dependence on new product development; rapid technological and market change; reliance on sales by others; management of growth; dependence on key personnel; rapid expansion; growth of the Internet; financial risk management; and future growth subject to risks. These factors and other factors which could cause actual results to differ materially are also discussed in the company's filings with the United States Securities and Exchange Commission, including Autonomy's Annual Report on Form 20-F and Registration Statements on Form F-1.

For more information, please contact:
Ian Black
Autonomy Corporation plc
+44 (0) 1223 448000
ianb@autonomy.com
Edward Bridges/Alastair Hetherington
Financial Dynamics
+44 207 831 3113
edward.bridges@fd.com
alastair.hetherington@fd.com
Kris Marubio
Autonomy Corporation plc
+1 415/243-9955
krism@us.autonomy.com
Kathleen Gratehouse
Schwartz Communications
+1 415/512-0770
autonomy@schwartz-pr.com

This is a selection of our forthcoming events, please visit our seminars page for more information.

Automatic Hyperlinks provided by IDOL Server 7

This is a small selection of the Autonomy case studies available, please visit our publications site at http://publications.autonomy.com/ for more information.

Automatic Hyperlinks provided by IDOL Server 7

+1 415 243 9955

Company
Technology
Functionality
Products
Solutions
Services
Customers
Partners
News & Events